Request SampleGlobal Enzyme Replacement Therapy Sales Market Report 2023
SKU ID : QYR-22288831 | Publishing Date : 02-Jan-2023 | No. of pages : 127
Market Analysis and Insights: Global Enzyme Replacement Therapy Market
Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.
Due to the COVID-19 pandemic, the global Enzyme Replacement Therapy market size is estimated to be worth US$ 11830 million in 2022 and is forecast to a readjusted size of US$ 29910 million by 2029 with a CAGR of 14.0% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Injectable Agents accounting for % of the Enzyme Replacement Therapy global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Gaucher Disease segment is altered to an % CAGR throughout this forecast period.
Global Enzyme Replacement Therapy key players include Johnson & Johnson, Allergan, AbbVie, etc. Global top three manufacturers hold a share about 95%.
North America is the largest market, with a share about 70%, followed by Europe, and Asia-Pacific, both have a share over 25 percent.
In terms of product, Oral Agents is the largest segment, with a share nearly 95%. And in terms of application, the largest application is MPS Disease, followed by Gastrointestinal Diseases, Gaucher Disease, Fabry Disease, etc.
Global Enzyme Replacement Therapy Scope and Market Size
The global Enzyme Replacement Therapy market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Enzyme Replacement Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Injectable Agents
Oral Agents
Segment by Application
Gaucher Disease
Fabry Disease
MPS Disease
Gastrointestinal Disease
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Sanofi
Takeda
BioMarin
AbbVie
Alexion
Allergan
Horizon Pharma
Johnson & Johnson
Actelion
Recordati Rare Diseases
Pfizer
Digestive Care
Leadiant Biosciences
Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.
Due to the COVID-19 pandemic, the global Enzyme Replacement Therapy market size is estimated to be worth US$ 11830 million in 2022 and is forecast to a readjusted size of US$ 29910 million by 2029 with a CAGR of 14.0% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Injectable Agents accounting for % of the Enzyme Replacement Therapy global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Gaucher Disease segment is altered to an % CAGR throughout this forecast period.
Global Enzyme Replacement Therapy key players include Johnson & Johnson, Allergan, AbbVie, etc. Global top three manufacturers hold a share about 95%.
North America is the largest market, with a share about 70%, followed by Europe, and Asia-Pacific, both have a share over 25 percent.
In terms of product, Oral Agents is the largest segment, with a share nearly 95%. And in terms of application, the largest application is MPS Disease, followed by Gastrointestinal Diseases, Gaucher Disease, Fabry Disease, etc.
Global Enzyme Replacement Therapy Scope and Market Size
The global Enzyme Replacement Therapy market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Enzyme Replacement Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Injectable Agents
Oral Agents
Segment by Application
Gaucher Disease
Fabry Disease
MPS Disease
Gastrointestinal Disease
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Sanofi
Takeda
BioMarin
AbbVie
Alexion
Allergan
Horizon Pharma
Johnson & Johnson
Actelion
Recordati Rare Diseases
Pfizer
Digestive Care
Leadiant Biosciences
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
24/7 Research Support
Phone: +1 (888) 690-5999 
